Current therapies for acute kidney injury remain primarily supportive and have failed to
reduce morbidity, mortality (> 50%), and associated costs. This prompted our studies in …

Incomplete recovery from acute kidney injury (AKI) can result in long-term functional deficits
and has been recognized as a major contributor to chronic kidney disease (CKD), which is …

Mesenchymal stem cells are currently considered as a promising tool for therapeutic
application in acute kidney injury (AKI) management. AKI is characterized by acute tubular …

Every year 13.3 million people suffer acute kidney injury (AKI), which is associated with a
high risk of death or development of long-term chronic kidney disease (CKD) in a substantial …

Acute kidney injury (AKI) is a common clinical complication, associated with poor outcomes
and the development of chronic kidney disease. Despite major advances in the …

Severe acute renal failure (ARF) remains a common, largely treatment-resistant clinical
problem with disturbingly high mortality rates. Therefore, we tested whether administration of …

The understanding of cellular sources of kidney regeneration has rapidly evolved in the last
decade. It is now believed that regeneration occurs predominantly from cells that reside …

Although the kidney has been suspected, though not definitively proven, to contain organ-
specific pluripotent stem cells, their role in regeneration after renal injury is uncertain (1–3) …

Background: Acute kidney injury (AKI) is emerging as a public health problem in developing
and developed countries. It affects up to 7% of hospitalized patients, with a higher …

Acute kidney injury carries severe consequences and has limited treatment options. Bone
marrow stem cells may offer the potential for treatment of acute kidney injury. The purpose of …